Substituted azabicyclic moieties for the treatment of disease (nicotinic acethylcholine receptor antagonists)
CA 2439960 A1 · Owner: Piotrowski, David W. · Inventors: Jacobsen, E. Jon; Piotrowski, David W.; Groppi, Vincent E. Jr.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides compounds of Formula (I): (F) Formula (I) wherein m1 is 0 or 1; m2 is 1 or 2; R1 is-H, alkyl, halogenated alkyl substituted alkyl, cycloakyl, or phenyl; R2 is -H alkyl, halogenated alkyl, substituted alkyl cycloalkyl, or phenyl, provided that when m1 is 1 at least one of R1 and R2 is -H; or a pharmaceutically acceptable salt pharmaceutical composition, a pure , enantiomer or racemic mixture thereof. The invention also provides a method for treating a disease or condition in a mammal wherein the .prop.7 nicotinic , acetylcholine receptor is implicated and for treating diseases where there is a sensory-gating deficit in a mammal comprising administering to a mammal …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 18, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.